MedPath

Effectiveness and Safety Evaluation of Treatment Regimen for Helicobacter pylori Infection Including Levofloxacin: A Prospective, Randomized Controlled Study

Phase 4
Conditions
Helicobector pylori
Registration Number
ChiCTR2400088791
Lead Sponsor
The First Affiliated Hospital of Xiamen University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1.Aged between 18 and 69 years old; 2. Individuals with a positive result in the 13C or 14C breath test, or confirmed as Helicobacter pylori infection through at least two of the following methods: rapid urease test, histopathology, Hp culture, and fecal Hp antigen test; 3. Have not received eradication therapy for Helicobacter pylori in the past; 4. Willing to undergo anti-Hp treatment and sign an informed consent form.

Exclusion Criteria

1.Individuals allergic to any investigational drug; 2. Individuals who have undergone partial or total gastrectomy; 3. Individuals with significant organ dysfunction such as respiratory, cardiac, hepatic, renal insufficiency, etc.; 4. Individuals who have used antibiotics or corticosteroids within 4 weeks prior to enrollment, or acid suppressants within 2 weeks prior to enrollment; 5. Pregnant or lactating women; 6. Individuals who are unwilling to sign the informed consent form.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
13C-UBT;
Secondary Outcome Measures
NameTimeMethod
compliance;
© Copyright 2025. All Rights Reserved by MedPath